News and Announcements
Antisense Therapeutics to Present at MS Conference
- Published August 31, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Antisense Therapeutics Ltd (ASX:ANP) has recently reported on data showing ATL1102 significantly reduces the number of active multiple sclerosis (MS) brain lesions that convert to ‘Black Holes’ is to be presented at the 7th Joint ECTRIMSACTRIMS Meeting in Paris, France 25-28 October 2017.
KEY TAKEAWAYS:
- The world’s largest international conference devoted to basic and clinical research in MS.
Professor Barkhof, said “the ATL1102 ‘Black Holes’ data is most compelling which is reflected in its selection for late-breaker poster presentation”.
Importantly, the positive effect of ATL1102 suggests that along with its action in reducing the number of new inflammatory brain lesions, ATL1102 may also be neuroprotective by reducing damage to axons in the lesions and thereby slow the MS disease progression.
Further information on the meeting can be found at https://www.ectrims-congress.eu/2017.html
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
